// App-Quantinova.ai

953 : Acquired Mutations within the JAK2 Kinase Domain Confer Resistance to JAK Inhibitors in an in Vitro model of a High-Risk Acute Lymphoblastic Leukemia

Researchers

Presenter

  • Charlotte EJ Downes

Principal Investigators

  • Barbara J McClure

  • Jacqueline Rehn

  • James Breen

  • John B Bruning

  • David T Yeung

  • Deborah L White

Medical Centers

  • Computational and Systems Biology Program, Precision Medicine Theme, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, SA, Australia

  • School of Biological Sciences, The University of Adelaide, Adelaide, SA, Australia

  • Adelaide Medical School, University of Adelaide, Adelaide, SA, Australia

  • Computational and Systems Biology Program, Precision Medicine Theme, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, SA, Australia

  • Computational and Systems Biology Program, Precision Medicine Theme, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, SA, Australia

  • Robinson Research Institute, University of Adelaide, Adelaide, SA, Australia

  • Cancer Program, Precision Medicine Theme,South Australian Health and Medical Research Institute,Adelaide,Australia

  • Department of Haematology,Royal Adelaide Hospital and SA Pathology,Adelaide,Australia

  • Australian and New Zealand Children's Haematology/Oncology Group, Brisbane, Australia

Locations

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • B-cell acute lymphoblastic leukemia

Biomarkers

  • Annexin V

  • Janus kinase

Drug/Treatment

  • Ruxolitinib phosphate

Outcome

  • N/A

Study Design

  • Dose Escalation

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved